Great Point Partners-backed VetnCare acquires Geary Veterinary Hospital in California

• The deal is VetnCare’s seventh acquisition since partnering with Great Point Partners and its second under chief executive officer Matt Kirchner
• Geary is led by Dr. Gillian Hamilton, a former CDC and Massachusetts public health epidemiologist, and Dr. Erica Weiss, who completed a residency in laboratory animal medicine
• The acquisition expands VetnCare’s presence in the East Bay, adding to a Northern California network offering specialties including oncology, ophthalmology, dermatology and orthopedic surgery

Great Point Partners-backed VetnCare has acquired Geary Veterinary Hospital, a veterinary practice based in Walnut Creek, California, for undisclosed terms.

Founded in 1979, Geary has served pets and families in the East Bay for nearly five decades and is led by Dr. Gillian Hamilton and Dr. Erica Weiss. The practice offers wellness and preventive care, diagnostics and imaging, surgery, dental care and senior pet care. Hamilton previously worked as an epidemiologist at the Centers for Disease Control and Prevention and as an infectious disease epidemiologist for the Massachusetts Department of Public Health, while Weiss completed a residency in laboratory animal medicine.

The deal marks VetnCare’s seventh acquisition since partnering with Great Point Partners and its second under chief executive officer Matt Kirchner, extending the company’s presence in the East Bay.

“Geary is exactly the type of locally established, clinician-led practice that makes VetnCare’s community stronger and will seamlessly integrate into the broader ecosystem,” said Eddie Hjerpe, principal at Great Point Partners. “This acquisition highlights the company’s ongoing momentum, and we look forward to supporting Matt and the broader team as they continue to thoughtfully expand VetnCare’s presence across Northern California.”

Great Point Partners, founded in 2003 and based in Greenwich, Connecticut, is a health care-focused investment firm managing approximately $1.7 billion of capital across private funds and a public life sciences equity strategy.

Editor’s note: This news brief was produced with the assistance of artificial intelligence.